Special Bulletin – Incyte jacks up Jakafi price
What’s really behind Incyte’s decision to boost the price of Jakafi – its MF drug already considered not too pricey for the UK and cost-ineffective – on the heels of patient appeals to lower the cost.
The story, Incyte’s official response and the reactions here.
Comments on: "Jakafi price increase – the story" (1)
From now on I will no longer call the company Incyte rather I will call them Insult.